US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
LOS ANGELES, May 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX) concerning possible violations of federal securities laws between March 30, 2017 and May 11, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced that the report was withdrawn due to “material inaccuracies.” On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. When this information was announced, Akari shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
